We are live on
!
Find out more
AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.94B
1-Year Est. Return
374.45%
This Fund
S&P 500
This Quarter
Est. Return
-6.02%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$302M
(+40%)
Cap. Flow
+$392M
Cap. Flow
% of AUM
37.44%
Top 10 Holdings %
Top 10 Hldgs %
55.13%
Holding
117
New
33
Increased
29
Reduced
19
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$17.7M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$17.6M |
| 3 |
NUVL
Nuvalent
NUVL
|
+$13.7M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$11.3M |
| 5 |
Mineralys Therapeutics
MLYS
|
+$8.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arvinas
ARVN
|
+$12.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$11.5M |
| 3 |
Spyre Therapeutics
SYRE
|
+$7.13M |
| 4 |
Arrowhead Research
ARWR
|
+$5.64M |
| 5 |
SLNO
Soleno Therapeutics
SLNO
|
+$3.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.37% |
| 2 | Financials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vera Therapeutics
VERA
$2.66B
| $8.53M | 0.81% |
355,143
-69,857
| -16% | -$2.24M |
|
|
27
CALL
Protagonist Therapeutics
PTGX
$8.64B
| $8.34M | 0.8% |
+172,500
| New | +$7.23M |
|
28
CALL
Corcept Therapeutics
CORT
$9.83B
| $8M | 0.76% |
+70,000
| New | +$4.26M |
|
29
Trevi Therapeutics
TRVI
$2.38B
| $7.86M | 0.75% |
+1,250,000
| New | +$5.96M |
|
|
30
Spyre Therapeutics
SYRE
$8.45B
| $7.77M | 0.74% |
481,678
-342,650
| -42% | -$7.13M |
|
31
Immunovant
IMVT
$8.2B
| $7.35M | 0.7% |
430,000
+330,000
| +330% | +$6.9M |
|
32
NewAmsterdam Pharma
NAMS
$3.47B
| $6.65M | 0.63% |
325,000
-100,000
| -24% | -$2.22M |
|
|
33
CALL
Vera Therapeutics
VERA
$2.66B
| $6.37M | 0.61% |
+265,000
| New | +$8.52M |
|
|
ORKA
34
Oruka Therapeutics
ORKA
$5.53B
| $5.6M | 0.53% |
545,362
+176,664
| +48% | +$2.2M |
|
35
Neurocrine Biosciences
NBIX
$17.4B
| $5.53M | 0.53% |
+50,000
| New | +$6.33M |
|
36
Avalo Therapeutics
AVTX
$957M
| $5.26M | 0.5% |
657,154
+106,389
| +19% | +$806K |
|
37
Viridian Therapeutics
VRDN
$2.05B
| $5.26M | 0.5% |
390,000
+230,386
| +144% | +$3.92M |
|
38
Lexeo Therapeutics
LXEO
$357M
| $5.14M | 0.49% |
+1,480,881
| New | +$6.56M |
|
|
39
Crinetics Pharmaceuticals
CRNX
$8.88B
| $5.11M | 0.49% |
152,252
-307,748
| -67% | -$11.5M |
|
40
CALL
Exelixis
EXEL
$14B
| $4.98M | 0.48% |
+135,000
| New | +$4.81M |
|
41
Rezolute
RZLT
$429M
| $4.93M | 0.47% |
1,700,000
+125,000
| +8% | +$544K |
|
42
Perspective Therapeutics
CATX
$333M
| $4.74M | 0.45% |
2,224,196
+924,196
| +71% | +$2.77M |
|
|
AUTL
43
Autolus Therapeutics
AUTL
$373M
| $4.72M | 0.45% |
3,045,000
-1,455,000
| -32% | -$2.95M |
|
44
Erasca
ERAS
$6.53B
| $4.58M | 0.44% |
3,341,519
+842,088
| +34% | +$1.45M |
|
45
PUT
Edgewise Therapeutics
EWTX
$4.18B
| $4.4M | 0.42% |
+200,000
| New | +$5.25M |
|
46
ProQR Therapeutics
PRQR
$248M
| $4.37M | 0.42% |
3,284,512
+459,512
| +16% | +$978K |
|
47
uniQure
QURE
$2.73B
| $4.24M | 0.4% |
+400,000
| New | +$5.61M |
|
|
PCSC
48
Perceptive Capital Solutions
PCSC
$123M
| $3.62M | 0.35% |
350,000
| – | – |
|
|
SLNO
49
DELISTED
Soleno Therapeutics
SLNO
| $3.57M | 0.34% |
50,000
-80,000
| -62% | -$3.9M |
|
|
INZY
50
DELISTED
Inozyme Pharma
INZY
| $3.52M | 0.34% |
3,867,710
-104,608
| -3% | -$145K |
|
Similar funds
FM
1SB
HCL
OCM
MWA
AF
NFG
HC
Affinity Asset Advisors's Q1 2025 Portfolio in Review
As of Q1 2025, Affinity Asset Advisors held 117 positions worth $1.05B, up 40% from $746M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Affinity Asset Advisors deployed $392M of net new capital in Q1 2025, opening 33 new positions and adding to 29 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 30,000 shares worth $16.8M.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 78% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $11.5M trimmed.
- Affinity Asset Advisors's largest Q1 2025 buy was State Street SPDR S&P 500 ETF Trust: 30,000 shares worth $16.8M.
- Affinity Asset Advisors added most to Travere Therapeutics in Q1 2025, an estimated $17.7M increase.
- Affinity Asset Advisors's biggest Q1 2025 reduction was Crinetics Pharmaceuticals, cutting an estimated $11.5M.
- Affinity Asset Advisors fully exited Arvinas in Q1 2025, selling an estimated $12.1M.
- Affinity Asset Advisors's ten largest holdings make up 55% of its $1.05B portfolio in Q1 2025.
- Affinity Asset Advisors opened 33 new positions and closed 19 in Q1 2025.
- Affinity Asset Advisors's portfolio value rose 40% quarter-over-quarter to $1.05B.
Based on Affinity Asset Advisors's 13F filing for Q1 2025, filed 14 May 2025.